Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease
Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, including dyslipidemia and Nonalcoholic Steatohepatitis (NASH), announced...
Old antibiotic compounds could become life-saving drugs
Turns out, discarded antibiotic compounds could be developed for new life-saving drugs.In the heyday of antibiotic development in the mid-20th century, many different chemical...
Sanofi, DNDi Seek EMA Review For Sleeping Sickness Drug
The Paris, France-based drugmaker said it is hoped that the treatment will contribute to the elimination of the disease.
The European Medicines Agency has accepted...
Nasal Spray Could Lower Risk Of Opioid Addiction
The animal study tested whether using nanotechnology enables the exclusive delivery of the drug into the brain and causes analgesia (pain relief). During the...
Blood vessel-on-a-chips show anti-cancer drug effects in human cells
Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...